文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machine
侵权投诉

Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machine

articles

binethepredictionoftwoseparateSVMclassi ersforeachofthemultiplekinases,wastestedbyusingthemtosearchdual-inhibitorsofcombinationsof9anticancerkinasetargetsEGFR,VEGFR,PDGFR,FGFR,Src,Lck,CDK1,CDK2,andGSK3.Thesekinasetargetswereselectedbecauseoftheirtherapeuticrelevanceandtheavailabilityofsuf cientnumberoftheknowninhibitorsanddual-inhibitors.The rstsixkinasesbelongtotheproteinkinasegroupPTKgroup,andthelastthreebelongtotheCMGCgrouprespectively.Basedondual-inhibitoravailability,wefocusedon11kinasepairsEGFR-PDGFR,EGFR-FGFR,EGFR-Src,VEG-FR-Lck,PDGFR-FGFR,PDGFR-Src,Src-Lck,CDK1-CDK2,CDK1-GSK3,CDK2-GSK3,andCDK1-VEGFR.The rst7kinasepairsareintra-PTKgroup,theeighthto10thareintra-CMGCgroup,andthe11thareinter-PTK-CMGCgroupkinasepairsrespectively,representativeofdifferenttypesofkinasepairs.Thesekinasepairsarefrequentlycoexpressedorcoactivatedinvariouscancers,22,23andtargetedbymultitargetagents9,10withgoodanticanceref cacies.InhibitorsofgrowthfactorreceptortyrosinekinasesEGFR,VEGFR,PDGFRandFGFRhavebeensuccessfullyusedforcancertreatments.10,24-28EGFRpro-motesproliferationandsurvival.24VEGFRregulatesangio-genesisandsurvival.26PDGFRmodulatesangiogenesisandgrowth,andisoneofthemultitargetsofseveralapprovedandclinicaltrialdrugs.10,27FGFRregulatesangiogenesisandcancerprogression,andisoneofthemultitargetsofseveralclinicaltrialdrugs.10,28Src-familykinasesSrcandLckmodulatemultiplepathwaysofcellgrowth,differentiation,migrationandsurvival,andarepartofthemultitargetsofseveralmarketedandclinicaltrialdrugs.10,29CDKspromotecellcycleprogression,theirinhibitionseverelylimitstheaberrantcell-cycleprocessintumorandinducesapoptosis,

(22)Gockel,I.;Moehler,M.;Frerichs,K.;Drescher,D.;Trinh,T.T.;

Duenschede,F.;Borschitz,T.;Schimanski,K.;Biesterfeld,S.;Herzer,K.;Galle,P.R.;Lang,H.;Junginger,T.;Schimanski,C.C.Co-expressionofreceptortyrosinekinasesinesophagealadenocarcinomaandsquamouscellcancer.Oncol.Rep.2008,20(4),845–50.

(23)Stommel,J.M.;Kimmelman,A.C.;Ying,H.;Nabioullin,R.;

Ponugoti,A.H.;Wiedemeyer,R.;Stegh,A.H.;Bradner,J.E.;Ligon,K.L.;Brennan,C.;Chin,L.;DePinho,R.A.Coactivationofreceptortyrosinekinasesaffectstheresponseoftumorcellstotargetedtherapies.Science2007,318(5848),287–90.

(24)Speake,G.;Holloway,B.;Costello,G.Recentdevelopments

relatedtotheEGFRasatargetforcancerchemotherapy.Curr.Opin.Pharmacol.2005,5(4),343–9.

(25)Moasser,M.M.TargetingthefunctionoftheHER2oncogenein

humancancertherapeutics.Oncogene2007,26(46),6577–92.(26)Zhong,H.;Bowen,J.P.Moleculardesignandclinicaldevelop-mentofVEGFRkinaseinhibitors.Curr.Top.Med.Chem.2007,7(14),1379–93.

(27)Lewis,N.L.Theplatelet-derivedgrowthfactorreceptorasa

therapeutictarget.Curr.Oncol.Rep.2007,9(2),89–95.

(28)Rusnati,M.;Presta,M.Fibroblastgrowthfactors/ broblastgrowth

factorreceptorsastargetsforthedevelopmentofanti-angiogenesisstrategies.Curr.Pharm.Des.2007,13(20),2025–44.

(29)Benati,D.;Baldari,C.T.SRCfamilykinasesaspotential

therapeutictargetsformalignanciesandimmunologicaldisorders.Curr.Med.Chem.2008,15(12),1154–65.1548

MOLECULARPHARMACEUTICSVOL.7,NO.5

Maetal.

andCDKinhibitorsarebeingdevelopedandtestedinclinicaltrialsforanticancertherapeutics.30GSK3modulatesglucosemetabolismandthefunctionofvariousproteins,andisassociatedwithneurodegenerativediseases,stroke,bipolardisorder,diabetesandcancer.31GSK3inhibitorshavestartedtoreachclinicaldevelopmentforthetreatmentofvariousdisorders.31

MultitargetVSperformancewastestedbyarigorousmethodthatassumesnoexplicitknowledgeofknownmultitargetagents,becausethenumberofknownmultitargetagentsisgenerallysmallformanytargetpairs.TheSVMofeachkinasewastrainedbyusingnon-dual-inhibitorsofthatkinase.ThecollectiveyieldofC-SVMofeachkinasepair(percentofknowndual-inhibitorsidenti edasdual-inhibitors)wasestimatedbyusingknowndual-inhibitorsofeachkinasepair.TargetselectivityofeachC-SVMwasassessedbyusingnon-dual-inhibitorsofthekinasepairandinhibitorsoftheother7kinases,outofthe9evaluatedkinases,notincludedinthekinasepair.Virtual-hitratesandfalse-hitratesinsearchinglargecompoundlibrarieswereevaluatedbyusing13.56millionPubChemcompounds,168thousandcompoundsfromtheMDLDrugDataReport(MDDR)database,and276-3,806MDDRcompoundssimilarinstructuralandphysicochemicalpropertiestotheknowndual-kinaseinhibitors.MDDRcontainsbiologicallyrelevantcompounds(activeagainstindividualmoleculartargetorbiologicalassay)andwell-de nedderivativesreportedinthepatentliterature,journals,meetingsandcongresses.PubChemandMDDRcontainhighpercentagesofinactiveoractivecompoundssigni cantlydifferentfromthedual-inhibitors,andtheeasilydistinguishablefeaturesmaymakeVSenrichmentsarti ciallygood.32Therefore,VSperformanceismorestrictlytestedbyusingasubsetofMDDRcompoundssimilartothedual-inhibitorssothatenrichmentisnotsimplyaseparationoftrivialphysico-chemicalfeatures.33

VSperformanceofC-SVMwasfurthercomparedwiththatofthreeVSmethods,whichincludetwopopularmoleculardockingsoftwareSur ex-DockandDOCKversion3.5.54attheDOCKBlasterserver,34asimilarity-based

(30)Schwartz,G.K.;Shah,M.A.Targetingthecellcycle:anew

approachtocancertherapy.J.Clin.Oncol.2005,23(36),9408–21.

(31)Medina,M.;Castro,A.Glycogensynthasekinase-3(GSK-3)

inhibitorsreachtheclinic.Curr.Opin.DrugDiscoVeryDeV.2008,11(4),533–43.

(32)Verdonk,M.L.;Berdini,V.;Hartshorn,M.J.;Mooij,W.T.;

Murray,C.W.;Taylor,R.D.;Watson,P.Virtualscreeningusingprotein-liganddocking:avoidingarti cialenrichment.J.Chem.Inf.Comput.Sci.2004,44(3),793–806.

(33)Huang,N.;Shoichet,B.K.;Irwin,J.J.Benchmarkingsetsfor

moleculardocking.J.Med.Chem.2006,49(23),6789–801.(34)Irwin,J.J.;Shoichet,B.K.;Mysinger,M.M.;Huang,N.;Colizzi,

F.;Wassam,P.;Cao,Y.Automateddockingscreens:afeasibilitystudy.J.Med.Chem.2009,52(18),5712–20.

上一页第4页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email